Sign in

    Timothy Daley

    Vice President and Senior Equity Research Analyst at Wells Fargo

    Timothy Daley is a Vice President and Senior Equity Research Analyst at Wells Fargo in San Francisco, specializing in the Life Sciences sector. He covers major life sciences and analytical instrument companies including Thermo Fisher, and over 24 stocks overall, and he has a documented 52.94% success rate with an average return of 1.11% according to TipRanks and Benzinga performance metrics. Daley began his career prior to joining Wells Fargo, accumulating experience as a Senior Equity Research Analyst and has held the Vice President title at Wells Fargo, with a career notable for steady coverage and a moderate success ranking. He holds relevant professional credentials and securities licensing, and operates from Wells Fargo’s San Francisco office.

    Timothy Daley's questions to CTLT leadership

    Timothy Daley's questions to CTLT leadership • Q4 2023

    Question

    Asked for specifics on the company's sterile fill/finish capacity, particularly for prefilled syringes. Also questioned why inventory balances haven't decreased yet despite supply chain normalization.

    Answer

    Close to 40% of the company's sterile fill/finish capacity is in prefilled syringes, and this is rapidly increasing to become the majority. Regarding inventory, management acknowledged it is a focus area. While receivables are easier to collect for quick cash, there is a significant opportunity to reduce inventory, which requires more process-oriented work that is now underway.

    Ask Fintool Equity Research AI